What is the current valuation of the antibodies market in South Korea?

The antibodies market in South Korea was valued at 7.61 $ Billion in 2024. Read More

What is the projected market size for the antibodies market in South Korea by 2035?

The market is projected to reach 31.7 $ Billion by 2035. Read More

What is the expected CAGR for the antibodies market in South Korea from 2025 to 2035?

The expected CAGR for the antibodies market during the forecast period 2025 - 2035 is 13.85 %. Read More

Which application segments are driving growth in the South Korean antibodies market?

The oncology segment is projected to grow from 1.52 $ Billion to 6.38 $ Billion, while infectious diseases are expected to rise from 2.28 $ Billion to 9.66 $ Billion. Read More

What types of antibodies are most prevalent in the South Korean market?

Monoclonal antibodies dominate the market, with a growth from 3.81 $ Billion to 15.83 $ Billion. Read More

How do the end-use segments contribute to the antibodies market in South Korea?

Research institutes are anticipated to grow from 3.05 $ Billion to 12.38 $ Billion, indicating a strong demand in this sector. Read More

What are the leading companies in the South Korean antibodies market?

Key players include AbbVie, Roche, Johnson & Johnson, and Merck & Co., among others. Read More

What modes of administration are utilized in the South Korean antibodies market?

Intravenous administration is expected to grow from 4.25 $ Billion to 17.85 $ Billion, highlighting its significance. Read More

How does the market for polyclonal antibodies compare to monoclonal antibodies in South Korea?

Polyclonal antibodies are projected to grow from 2.28 $ Billion to 9.66 $ Billion, but monoclonal antibodies show a more substantial increase. Read More

What factors are influencing the growth of the antibodies market in South Korea?

The increasing prevalence of chronic diseases and advancements in biotechnology are likely driving the market's growth. Read More

South Korea Antibodies Market

ID: MRFR/HC/50194-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

South Korea Antibodies Market Research Report By Type (Monoclonal Antibodies, Polyclonal Antibodies, Intravenous Immunoglobulin), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Neurology), By End Use (Hospitals, Diagnostic Laboratories, Research Institutes) and By Mode of Administration (Subcutaneous, Intravenous, Intramuscular) - Growth & Industry Forecast 2025 To 2035

South Korea Antibodies Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Autoimmune Diseases
  3. 4.1.3 Infectious Diseases
  4. 4.1.4 Neurology
2. 4.2 Life Sciences, BY Type (USD Billion)
  1. 4.2.1 Monoclonal Antibodies
  2. 4.2.2 Polyclonal Antibodies
  3. 4.2.3 Intravenous Immunoglobulin
3. 4.3 Life Sciences, BY End Use (USD Billion)
  1. 4.3.1 Hospitals
  2. 4.3.2 Diagnostic Laboratories
  3. 4.3.3 Research Institutes
4. 4.4 Life Sciences, BY Mode of Administration (USD Billion)
  1. 4.4.1 Subcutaneous
  2. 4.4.2 Intravenous
  3. 4.4.3 Intramuscular
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bristol-Myers Squibb (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GSK (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY TYPE
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY END USE
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Billion)
14. 6.14 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 LIFE SCIENCES, BY END USE, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY END USE, 2024 TO 2035 (USD Billion)
18. 6.18 LIFE SCIENCES, BY MODE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY MODE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.2.4 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea Life Sciences Market Segmentation

Life Sciences By Application (USD Billion, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases
Neurology

Life Sciences By Type (USD Billion, 2025-2035)

Monoclonal Antibodies
Polyclonal Antibodies
Intravenous Immunoglobulin

Life Sciences By End Use (USD Billion, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutes

Life Sciences By Mode of Administration (USD Billion, 2025-2035)

Subcutaneous
Intravenous
Intramuscular

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”